Research programme: txNK cell therapies - bit.bio
Latest Information Update: 22 Dec 2023
At a glance
- Originator bit.bio
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer
Most Recent Events
- 04 Dec 2023 txNK cell therapy - bit.bio therapeutics is available for licensing as of 04 Dec 2023 (bit.bio therapeutics website, December 2023)
- 04 Dec 2023 Early research in Autoimmune disorders in United Kingdom (Parenteral) (bit.bio therapeutics pipeline, December 2023)
- 04 Dec 2023 Early research in Cancer in United Kingdom (Parenteral) (bit.bio therapeutics pipeline, December 2023)